---
title: "4547.JP (4547.JP) — Related News"
type: "Symbol"
locale: "en"
url: "https://longbridge.com/en/quote/4547.JP/news.md"
symbol: "4547.JP"
name: "4547.JP"
parent: "https://longbridge.com/en/quote/4547.JP.md"
datetime: "2026-05-20T19:09:37.776Z"
locales:
  - [en](https://longbridge.com/en/quote/4547.JP/news.md)
  - [zh-CN](https://longbridge.com/zh-CN/quote/4547.JP/news.md)
  - [zh-HK](https://longbridge.com/zh-HK/quote/4547.JP/news.md)
---

# 4547.JP (4547.JP) — Related News

### [Kissei Pharmaceutical's (TSE:4547) Solid Earnings May Rest On Weak Foundations](https://longbridge.com/en/news/286824222.md)
*2026-05-18T22:05:47.000Z*
> Kissei Pharmaceutical's recent earnings appear solid, but concerns arise from a significant contribution of JP¥18b from 

### [Amgen Japanese Partner Urges Caution On Tavneos Use](https://longbridge.com/en/news/286794592.md)
*2026-05-18T15:18:42.000Z*
> Amgen's Japanese partner, Kissei Pharmaceutical, has advised doctors to avoid prescribing Tavneos to new patients due to

### [Over 8,000 people have taken it! Vasculitis medication causes 20 deaths in Japan, drug companies call for a suspension of the drug](https://longbridge.com/en/news/286640523.md)
*2026-05-16T09:05:47.000Z*
> The vasculitis treatment drug TAVNEOS has led to the deaths of 20 patients in Japan, prompting KISSEI Pharmaceutical Ind

### [Kissei Pharmaceutical (TSE:4547) One Off Gain Lifts Margin And Tests Bullish Earnings Narrative](https://longbridge.com/en/news/286077464.md)
*2026-05-12T10:11:30.000Z*
> Kissei Pharmaceutical (TSE:4547) reported FY 2026 Q4 revenue of ¥24.8b and Basic EPS of ¥66.70, with trailing twelve mon

### [Kissei Pharmaceutical Swings to Operating Loss but Lifts Payouts and Eyes Profit Recovery](https://longbridge.com/en/news/285902787.md)
*2026-05-11T08:04:33.000Z*
> Kissei Pharmaceutical reported a fiscal 2026 net sales increase of 10.3% to ¥97.4 billion but faced an operating loss of

### [Jefferies Sticks to Their Buy Rating for Kissei Pharmaceutical Co (KSPHF)](https://longbridge.com/en/news/284995207.md)
*2026-05-03T12:26:19.000Z*
> Jefferies analyst Miyabi Yamakita has maintained a Buy rating for Kissei Pharmaceutical Co (KSPHF) with a price target o

### [Kissei Launches Yselty in Japan, Expanding Global Uterine Fibroid Treatment Portfolio](https://longbridge.com/en/news/279700044.md)
*2026-03-19T01:22:17.000Z*
> Kissei Launches Yselty in Japan, Expanding Global Uterine Fibroid Treatment Portfolio